CL2009001009A1 - Metodo para inhibir la espermatogenesis en un hombre que comprende administrarle un agonista del receptor de androgenos y una composicion que comprende un compuesto derivado de 19-norpregnanos 21 sustituidos. - Google Patents

Metodo para inhibir la espermatogenesis en un hombre que comprende administrarle un agonista del receptor de androgenos y una composicion que comprende un compuesto derivado de 19-norpregnanos 21 sustituidos.

Info

Publication number
CL2009001009A1
CL2009001009A1 CL2009001009A CL2009001009A CL2009001009A1 CL 2009001009 A1 CL2009001009 A1 CL 2009001009A1 CL 2009001009 A CL2009001009 A CL 2009001009A CL 2009001009 A CL2009001009 A CL 2009001009A CL 2009001009 A1 CL2009001009 A1 CL 2009001009A1
Authority
CL
Chile
Prior art keywords
man
administering
substituted
composition
receptor agonist
Prior art date
Application number
CL2009001009A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2009001009A1 publication Critical patent/CL2009001009A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Abstract

Método para inhibir la espermatogénesis en un hombre que comprende administrarle un agonista del receptor de andrógenos y una composición que comprende un compuesto derivado de 19-norpregnanos 21 sustituidos.
CL2009001009A 2008-04-28 2009-04-28 Metodo para inhibir la espermatogenesis en un hombre que comprende administrarle un agonista del receptor de androgenos y una composicion que comprende un compuesto derivado de 19-norpregnanos 21 sustituidos. CL2009001009A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4844408P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CL2009001009A1 true CL2009001009A1 (es) 2009-06-19

Family

ID=40756947

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001009A CL2009001009A1 (es) 2008-04-28 2009-04-28 Metodo para inhibir la espermatogenesis en un hombre que comprende administrarle un agonista del receptor de androgenos y una composicion que comprende un compuesto derivado de 19-norpregnanos 21 sustituidos.

Country Status (4)

Country Link
AR (1) AR072781A1 (es)
CL (1) CL2009001009A1 (es)
TW (1) TW200950788A (es)
WO (1) WO2009134713A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054197A1 (en) * 2014-09-30 2016-04-07 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders

Also Published As

Publication number Publication date
AR072781A1 (es) 2010-09-22
WO2009134713A1 (en) 2009-11-05
TW200950788A (en) 2009-12-16

Similar Documents

Publication Publication Date Title
PH12013501319A1 (en) Fatty acid acetylated salicylates and their uses
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
BR112016000299A8 (pt) composições, uso de uma composição, método para o combate dos fungos fitopatogênicos e uso dos componentes
DOP2011000104A (es) Combinacion de una insulina y un agonista de glp-1
EA201390843A1 (ru) Применение агониста toll-подобного рецептора для лечения рака
ECSP13012534A (es) Composición farmacéutica
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
CL2011000604A1 (es) Compuestos derivados de multiheteroarilo, inhibidores de h-pgds, composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades inflamatorias y alergicas.
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
NI201400042A (es) 2 - tiopirimidinonas
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
HN2011001247A (es) Inhibidores de cinana akt y p70 s6
MX2009013982A (es) Composiciones que comprenden inhibidores de triptofano hidroxilasa.
BR112012014669A2 (pt) componente para artigo de fumar, artigo de fumar e método
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
CU20090200A7 (es) Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas
PE20141584A1 (es) Uso de un inhibidor de aromatasa para el tratamiento del hipogonadismo y enfermedades relacionadas
BRPI1009375A2 (pt) derivados inibidores de hsp90, composições que os contém e utilização
AR072425A1 (es) Uso de nifurtimox para el tratamiento de giardiasis
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia